Ftse Mib
32.891,64
0,69%
DAX
18.069,58
0,27%
S&P 500
5.431,60
-0,04%
NASDAQ
17.688,88
0,12%
Bitcoin
66.122,48
-0,78%
Registration Strip Icon for default Registrati gratuitamente per ottenere quotazioni in tempo reale, grafici interattivi, flusso di opzioni in tempo reale e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ InflaRx NV (IFRX) InflaRx NV (IFRX) Notizie

InflaRx NV

IFRX
1,56
0,00 (0,00%)
Pre Mercato
Ultimo aggiornamento: 10:00:00
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
05/6/202423:07EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
05/6/202418:00GLOBEInflaRx Hosts R&D Event Highlighting the Promise of INF904
21/5/202422:15EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
21/5/202420:30GLOBEInflaRx Presents New Analysis of PANAMO Phase III Trial in..
08/5/202414:43EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
08/5/202413:30GLOBEInflaRx Reports First Quarter 2024 Financial Results and..
30/4/202413:30GLOBEInflaRx to Host Virtual R&D Event on June 5, 2024 and..
24/4/202413:30GLOBEInflaRx to Participate in Capital One Securities 1st Annual..
21/3/202412:00GLOBEInflaRx Reports Full Year 2023 Results and Announces INF904..
19/3/202412:30GLOBEInflaRx to Announce Development Plans for INF904 and 2023..
22/2/202413:30GLOBEInflaRx Appoints Jan Medina as Head of Investor Relations
25/1/202414:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
25/1/202413:30GLOBEInflaRx Announces Initiation of its Commitment Program for..
04/1/202422:16EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
04/1/202413:00GLOBEInflaRx Announces Positive Topline Results from the Multiple..
06/11/202314:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
06/11/202313:30GLOBEInflaRx Announces First Patient Dosed in Phase III Trial..
01/11/202313:04EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
01/11/202312:30GLOBEInflaRx Reports Third Quarter 2023 Financial Results and..
11/9/202314:45EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
11/9/202313:00GLOBEInflaRx Announces Positive Topline Results from the Single..
30/8/202314:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
30/8/202313:30GLOBEInflaRx’s Marketing Authorization Application (MAA) for..
10/8/202314:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
10/8/202313:30GLOBEInflaRx Reports Second Quarter 2023 Financial Results &..
12/7/202322:01EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
12/7/202306:15EDGAR2Form EFFECT - Notice of Effectiveness
30/6/202322:06EDGAR2Form F-3 - Registration statement by foreign private issuers
28/6/202314:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
28/6/202313:30GLOBEInflaRx Appoints Dr. Camilla Chong as Chief Medical Officer
21/6/202313:00GLOBEInflaRx Announces Commercial Launch of Gohibic (vilobelimab)..
Apertura: Min: Max:
Chiusura: 1,56

La tua Cronologia

NASDAQ
IFRX
InflaRx NV
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network